These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 34310688)

  • 1. Direct oral anticoagulants in patients with nonvalvular atrial fibrillation and extreme body weight.
    Bodega F; Russi A; Melillo F; Blunda F; Rubino C; Leo G; Cappelletti A; Mazzone P; Mattiello P; Della Bella P; Castiglioni A; Alfieri O; De Bonis M; Montorfano M; Tresoldi M; Filippi M; Salerno A; Cera M; Zangrillo A; Alberto M; Godino C;
    Eur J Clin Invest; 2022 Jan; 52(1):e13658. PubMed ID: 34310688
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inappropriate dose of nonvitamin-K antagonist oral anticoagulants: prevalence and impact on clinical outcome in patients with nonvalvular atrial fibrillation.
    Godino C; Bodega F; Melillo F; Rubino F; Parlati ALM; Cappelletti A; Mazzone P; Mattiello P; Della Bella P; Castiglioni A; Alfieri O; De Bonis M; Montorfano M; Tresoldi M; Filippi M; Zangrillo A; Salerno A; Cera M; Margonato A;
    J Cardiovasc Med (Hagerstown); 2020 Oct; 21(10):751-758. PubMed ID: 32740435
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Comparison of Inappropriate-Low-Doses Use among 4 Direct Oral Anticoagulants in Patients with Atrial Fibrillation: From the Database of a Single-Center Registry.
    Sato T; Aizawa Y; Fuse K; Fujita S; Ikeda Y; Kitazawa H; Takahashi M; Okabe M
    J Stroke Cerebrovasc Dis; 2018 Nov; 27(11):3280-3288. PubMed ID: 30121155
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and efficacy of direct oral anticoagulants (DOACs) in very elderly patients (≥85 years old) with non-valvular atrial fibrillation.
    Rubino C; Blunda F; Bodega F; Melillo F; Russi A; Mattiello P; Salerno A; Cera M; Margonato D; Mazzone P; Della Bella P; Castiglioni A; Alfieri O; DE Bonis M; Montorfano M; Filippi M; Tresoldi M; Cappelletti A; Zangrillo A; Margonato A; Godino C;
    Minerva Med; 2023 Apr; 114(2):137-147. PubMed ID: 34180639
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of safety and efficacy outcomes of direct oral anticoagulants versus warfarin in normal and extreme body weights for the treatment of atrial fibrillation or venous thromboembolism.
    Novak AR; Shakowski C; Trujillo TC; Wright GC; Mueller SW; Kiser TH
    J Thromb Thrombolysis; 2022 Aug; 54(2):276-286. PubMed ID: 35689140
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical Benefit of Direct Oral Anticoagulants Versus Vitamin K Antagonists in Patients with Atrial Fibrillation and Bioprosthetic Heart Valves.
    Russo V; Carbone A; Attena E; Rago A; Mazzone C; Proietti R; Parisi V; Scotti A; Nigro G; Golino P; D'Onofrio A
    Clin Ther; 2019 Dec; 41(12):2549-2557. PubMed ID: 31735436
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Real-World Comparative Effectiveness, Safety, and Health Care Costs of Oral Anticoagulants in Nonvalvular Atrial Fibrillation Patients in the U.S. Department of Defense Population.
    Gupta K; Trocio J; Keshishian A; Zhang Q; Dina O; Mardekian J; Rosenblatt L; Liu X; Hede S; Nadkarni A; Shank T
    J Manag Care Spec Pharm; 2018 Nov; 24(11):1116-1127. PubMed ID: 30212268
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparing the Efficacy and Safety of Direct Oral Anticoagulants With Warfarin in the Morbidly Obese Population With Atrial Fibrillation.
    Kido K; Ngorsuraches S
    Ann Pharmacother; 2019 Feb; 53(2):165-170. PubMed ID: 30130979
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of the Safety and Effectiveness of Four Direct Oral Anticoagulants in Japanese Patients with Nonvalvular Atrial Fibrillation Using Real-World Data.
    Enomoto A; Mano Y; Kawano Y; Nishikawa T; Aoyama T; Sasaki Y; Nagata M; Takahashi H
    Biol Pharm Bull; 2021; 44(9):1294-1302. PubMed ID: 34471057
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Low drug levels and thrombotic complications in high-risk atrial fibrillation patients treated with direct oral anticoagulants.
    Testa S; Paoletti O; Legnani C; Dellanoce C; Antonucci E; Cosmi B; Pengo V; Poli D; Morandini R; Testa R; Tripodi A; Palareti G
    J Thromb Haemost; 2018 May; 16(5):842-848. PubMed ID: 29532628
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Real-World Observational Study of Hospitalization and Health Care Costs Among Nonvalvular Atrial Fibrillation Patients Prescribed Oral Anticoagulants in the U.S. Medicare Population.
    Amin A; Keshishian A; Trocio J; Dina O; Le H; Rosenblatt L; Liu X; Mardekian J; Zhang Q; Baser O; Nadkarni A; Vo L
    J Manag Care Spec Pharm; 2018 Sep; 24(9):911-920. PubMed ID: 30156450
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Direct Oral Anticoagulants in Patients With Nonvalvular Atrial Fibrillation and Low Body Weight.
    Lee SR; Choi EK; Park CS; Han KD; Jung JH; Oh S; Lip GYH
    J Am Coll Cardiol; 2019 Mar; 73(8):919-931. PubMed ID: 30819360
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Periprocedural Outcomes of Direct Oral Anticoagulants Versus Warfarin in Nonvalvular Atrial Fibrillation.
    Nazha B; Pandya B; Cohen J; Zhang M; Lopes RD; Garcia DA; Sherwood MW; Spyropoulos AC
    Circulation; 2018 Oct; 138(14):1402-1411. PubMed ID: 29794081
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Body Mass Index Influence on the Clinical Outcomes for Nonvalvular Atrial Fibrillation Patients Admitted to a Hospital Treated with Direct Oral Anticoagulants: A Retrospective Cohort Study.
    Li X; Zuo C; Ji Q; Xue Y; Wang Z; Lv Q
    Drug Des Devel Ther; 2021; 15():1931-1943. PubMed ID: 33986592
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of the efficacy of direct oral anticoagulants (DOACs) in comparison to warfarin in morbidly obese patients.
    Kalani C; Awudi E; Alexander T; Udeani G; Surani S
    Hosp Pract (1995); 2019 Oct; 47(4):181-185. PubMed ID: 31580732
    [No Abstract]   [Full Text] [Related]  

  • 16. A nationwide registry study to compare bleeding rates in patients with atrial fibrillation being prescribed oral anticoagulants.
    Halvorsen S; Ghanima W; Fride Tvete I; Hoxmark C; Falck P; Solli O; Jonasson C
    Eur Heart J Cardiovasc Pharmacother; 2017 Jan; 3(1):28-36. PubMed ID: 27680880
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Switching to Another Oral Anticoagulant and Drug Discontinuation Among Elderly Patients With Nonvalvular Atrial Fibrillation Treated With Different Direct Oral Anticoagulants.
    Baker CL; Dhamane AD; Rajpura J; Mardekian J; Dina O; Russ C; Rosenblatt L; Lingohr-Smith M; Lin J
    Clin Appl Thromb Hemost; 2019; 25():1076029619870249. PubMed ID: 31418293
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of the short-term risk of bleeding and arterial thromboembolic events in nonvalvular atrial fibrillation patients newly treated with dabigatran or rivaroxaban versus vitamin K antagonists: a French nationwide propensity-matched cohort study.
    Maura G; Blotière PO; Bouillon K; Billionnet C; Ricordeau P; Alla F; Zureik M
    Circulation; 2015 Sep; 132(13):1252-60. PubMed ID: 26199338
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Survey of Direct Oral Anticoagulant Cessation in General Surgery and Outcomes in Patients with Nonvalvular Atrial Fibrillation.
    Kawabata M; Goya M; Maeda S; Yagishita A; Takahashi Y; Sasano T; Hirao K
    Int Heart J; 2020 Sep; 61(5):905-912. PubMed ID: 32921660
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Real-World Observational Study of Hospitalization and Health Care Costs Among Nonvalvular Atrial Fibrillation Patients Prescribed Oral Anticoagulants in the U.S. Medicare Population.
    Amin A; Keshishian A; Trocio J; Dina O; Le H; Rosenblatt L; Liu X; Mardekian J; Zhang Q; Baser O; Nadkarni A; Vo L
    J Manag Care Spec Pharm; 2020 May; 26(5):639-651. PubMed ID: 32347184
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.